Serum gamma-glutamyl transferase (GGT) activity is a general clinical marker of excessive alcohol consumption, and GGT reflects changes in oxidative stress and implicated in the progression of hypertension. Recent guidelines classify persons with above-optimal blood pressure (BP) but not clinical hypertension as having prehypertension for a systolic BP (SBP) of 120 to 139 mmHg and/or a diastolic BP (DBP) of 80 to 89 mmHg; however, only limited data are available on the association between serum GGT and this entity among community-dwelling men in Japan. We performed a cross-sectional study to examine whether serum GGT was associated with prehypertension. Study participants (754 men, age 56 +/- 15 years) without a clinical history of stroke, transient ischemic attack, myocardial infarction, angina, or renal failure were recruited from a single community. Thirty-seven percent of participants had prehypertension and 39.3% had hypertension. Multiple regression analysis using SBP and DBP as objective variables, adjusted for risk factors as explanatory variables, showed that log GGT was significantly and independently associated with elevated SBP (beta = 0.109, P = 0.006) and DBP (beta = 0.238, P < 0.001). Compared with participants in the lowest tertile of serum GGT (< 29 IU/L), the multivariate-adjusted odds ratio (OR) (95% CI) for prehypertension was 1.73 (1.06-2.81) for the middle tertile (29-53 IU/L) and 2.37 (1.31-4.31) for the highest tertile (> 53 IU/L). Moreover, the respective ORs for hypertension were 1.82 (1.04-3.18) and 3.11 (1.61-6.03). These results suggest that higher serum GGT levels are associated with prehypertension or hypertension in the general male population.

Download full-text PDF

Source
http://dx.doi.org/10.1620/tjem.216.213DOI Listing

Publication Analysis

Top Keywords

serum ggt
16
association serum
8
serum gamma-glutamyl
8
gamma-glutamyl transferase
8
community-dwelling men
8
associated prehypertension
8
ggt
7
prehypertension
6
serum
5
hypertension
5

Similar Publications

Brucellosis is a highly contagious zoonotic bacterial disease. It has considerable negative consequences on the animal production industry worldwide. The objective of this study was to investigate the genetic and molecular variations in Shami goat susceptible to Brucella infection.

View Article and Find Full Text PDF

The Association Between Serum Gamma-Glutamyl Transferase and Gastrointestinal Cancer Risk: A Systematic Review and Meta-Analysis.

Cancer Med

January 2025

Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.

Background: Gamma-glutamyl transferase (GGT) has been shown to have associations with several diseases including cancers. Previous studies have investigated the effect of GGT levels on the gastrointestinal (GI) cancer incidence. We aim to systematically investigate these studies to provide better insights into the interrelationship between GGT and GI cancers.

View Article and Find Full Text PDF

Hepatic encephalopathy (HE) is a syndrome that arises from acute or chronic liver failure. This study was devised to assess the impact of a combination of boswellic acid (BA) and low doses of gamma radiation (LDR) on thioacetamide (TAA)-induced HE in an animal model. The effect of daily BA treatment (175 mg/kg body weight, for four weeks) and/or fractionated low-dose γ-radiation (LDR; 0.

View Article and Find Full Text PDF

Background: Elexacaftor-tezacaftor-ivacaftor (ETI) has significantly improved the clinical course of people with cystic fibrosis (pwCF) and eligible CFTR variants. In this study, we prospectively evaluated liver elastography, liver fibrosis indices and liver tests in children with CF aged 6-12 years started on ETI therapy.

Methods: Body mass index, sweat test, percent predicted forced expiratory volume in one second, serum markers of liver injury or portal hypertension, liver fibrosis indices, controlled attenuation parameter and liver stiffness were assessed before starting ETI and three and twelve months post-ETI, according to new international guidelines.

View Article and Find Full Text PDF

Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.

J Hepatol

January 2025

Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917). Electronic address:

Background And Aims: Bulevirtide (BLV) 2 mg/day is EMA approved for treatment of compensated chronic hepatitis due to Delta virus (HDV) infection, however real-life data in large cohorts of patients with cirrhosis are lacking.

Methods: Consecutive HDV-infected patients with cirrhosis starting BLV 2 mg/day since September 2019 were included in a European retrospective multicenter real-life study (SAVE-D). Patient characteristics before and during BLV treatment were collected.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!